China Medical System Holdings Ltd banner
C

China Medical System Holdings Ltd
HKEX:867

Watchlist Manager
China Medical System Holdings Ltd
HKEX:867
Watchlist
Price: 13.37 HKD -2.62%
Market Cap: HK$32.6B

China Medical System Holdings Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

China Medical System Holdings Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
C
China Medical System Holdings Ltd
HKEX:867
Operating Income
¥1.6B
CAGR 3-Years
-24%
CAGR 5-Years
-10%
CAGR 10-Years
4%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Operating Income
¥6.6B
CAGR 3-Years
37%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Operating Income
¥9B
CAGR 3-Years
42%
CAGR 5-Years
6%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Operating Income
¥4.8B
CAGR 3-Years
13%
CAGR 5-Years
3%
CAGR 10-Years
4%
Zhejiang Nhu Co Ltd
SZSE:002001
Operating Income
¥7.8B
CAGR 3-Years
22%
CAGR 5-Years
13%
CAGR 10-Years
35%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Operating Income
¥3.7B
CAGR 3-Years
N/A
CAGR 5-Years
203%
CAGR 10-Years
N/A
No Stocks Found

China Medical System Holdings Ltd
Glance View

Market Cap
32.6B HKD
Industry
Pharmaceuticals

China Medical System Holdings Ltd., a notable player in the Chinese pharmaceutical landscape, has woven a strategy that cleverly integrates proprietary drug development with a robust marketing apparatus. Established in 1995 and headquartered in Shenzhen, the company has developed a knack for identifying pharmaceuticals and medical devices with promising potential. Their business model hinges on acquiring exclusive rights to a carefully curated portfolio of international products, which they then introduce to the burgeoning Chinese market. By leveraging their deep understanding of market dynamics and regulatory environments, they effectively roll out these products, ensuring that they meet local demand and adhere to high compliance standards. The company's revenue engine is powered predominantly by its dynamic sales and marketing network which spans across mainland China. They employ a multifaceted distribution model, partnering with an extensive range of hospitals and healthcare providers to facilitate widespread adoption of their products. But what truly sets China Medical System Holdings apart is its focus on products that are already well advanced within their lifecycle, minimizing the usual risks associated with early-stage pharmaceutical development. This strategic approach not only ensures steady cash flows but also reduces overhead costs associated with R&D, allowing them to reinvest profits into acquiring new products and expanding their market footprint. As such, their business thrives on a cycle of discernment and targeted expansion, positioning them as a formidable entity in the healthcare sector.

Intrinsic Value
17.06 HKD
Undervaluation 22%
Intrinsic Value
Price HK$13.37
C

See Also

What is China Medical System Holdings Ltd's Operating Income?
Operating Income
1.6B CNY

Based on the financial report for Dec 31, 2025, China Medical System Holdings Ltd's Operating Income amounts to 1.6B CNY.

What is China Medical System Holdings Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
4%

Over the last year, the Operating Income growth was -6%. The average annual Operating Income growth rates for China Medical System Holdings Ltd have been -24% over the past three years , -10% over the past five years , and 4% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett